Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Purpose Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are ‘must-test’ biomarkers in the molecular diagnostics of advanced- stage lung cancer patients. Although single-gene assays are currently considered the gold standard for these genes, next-generation sequencing (NGS) tests are being introduced to clinical practices. We compared the results of current diagnostics and aimed to suggest timely effective guidance for their clinical use. Materials and Methods Patients with lung cancer who received both conventional single-gene assays and subsequent targeted NGS testing were enrolled, and the results of their tests were compared. Results A total of 241 patients were enrolled, and the EGFR real-time polymerase chain reaction, ALK fluorescence in situ hybridization (FISH), and ROS1 FISH assays exhibited 92.9%, 99.6%, and 99.5% concordance with the NGS tests, respectively. The discordant cases were mostly false-negatives of the single-gene assays, probably due to technical limitation. Of 158 cases previously designated as wild-type, EGFR, ALK, and ROS1 alterations were identified in 10.1%, 1.9%, and 1.3%, respectively, and other targetable alterations were identified in 36.1% of the cases. Of patients with additionally identified actionable alterations, 32.6% (31/95) received matched therapy with a clinical benefit of 48.4% (15/31). Conclusion Even though the conventional and NGS methods were concordant in the majority of cases, NGS testing still revealed a considerable number of additional EGFR, ALK, and ROS1 alterations, as well as other targetable alterations, in Korean advanced-stage lung cancer patients. Given the high frequency of EGFR and other targetable mutations identified in the present study, NGS testing is highly recommended in the diagnosis of Korean lung cancer patients.
Abstract
Purpose Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are ‘must-test’ biomarkers in the molecular diagnostics of advanced- stage lung cancer patients. Although single-gene assays are currently considered the gold standard for these genes, next-generation sequencing (NGS) tests are being introduced to clinical practices. We compared the results of current diagnostics and aimed to suggest timely effective guidance for their clinical use. Materials and Methods Patients with lung cancer who received both conventional single-gene assays and subsequent targeted NGS testing were enrolled, and the results of their tests were compared. Results A total of 241 patients were enrolled, and the EGFR real-time polymerase chain reaction, ALK fluorescence in situ hybridization (FISH), and ROS1 FISH assays exhibited 92.9%, 99.6%, and 99.5% concordance with the NGS tests, respectively. The discordant cases were mostly false-negatives of the single-gene assays, probably due to technical limitation. Of 158 cases previously designated as wild-type, EGFR, ALK, and ROS1 alterations were identified in 10.1%, 1.9%, and 1.3%, respectively, and other targetable alterations were identified in 36.1% of the cases. Of patients with additionally identified actionable alterations, 32.6% (31/95) received matched therapy with a clinical benefit of 48.4% (15/31). Conclusion Even though the conventional and NGS methods were concordant in the majority of cases, NGS testing still revealed a considerable number of additional EGFR, ALK, and ROS1 alterations, as well as other targetable alterations, in Korean advanced-stage lung cancer patients. Given the high frequency of EGFR and other targetable mutations identified in the present study, NGS testing is highly recommended in the diagnosis of Korean lung cancer patients.
참고문헌 (25)
- Lindeman NI, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors : guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology", J Thorac Oncol, 13, pp.323~358 (2018)
- 심효섭, "Molecular Testing of Lung Cancers", Journal of Pathology and Translational Medicine, 51(3), pp.242~254 (2017), 대한병리학회[DOI]
- Jordan EJ, "Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies", Cancer Discov, 7, pp.596~609 (2017)
- Hagemann IS, "Clinical next-generation sequencing in patients with non-small cell lung cancer", Cancer, 121, pp.631~639 (2015)
- Pennell NA, "Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model", J Clin Oncol, 36(15 Suppl), pp.9031~ (2018)
- Shao D, "A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma", Sci Rep, 6, pp.22338~ (2016)
- Cha YJ, "Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements", PLoS One, 9, pp.e103333~ (2014)
- Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer : a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
- Legras A, "Validity of targeted next-generation sequencing in routine care for identifying clinically relevant molecular profiles in non-small-cell lung cancer : results of a 2-year experience on 1343 samples", J Mol Diagn, 20, pp.550~564 (2018)
- Yu G, "EGFR muta-tion L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma", Int J Clin Exp Pathol, 8, pp.8603~8606 (2015)
- Wu SG, "Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma", Eur Respir J, 32, pp.924~930 (2008)
- Tuononen K, "Comparison of targeted next-generation sequencing(NGS)and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS", Genes Chromosomes Cancer, 52, pp.503~511 (2013)
- Kauffmann-Guerrero D, "NSCLC patients harbouring rare or complex EGFR mutations are more often smokers and might not benefit from first-line tyrosine kinase inhibitor therapy", Respiration, 95, pp.169~176 (2018)
- Tu HY, "A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer", Lung Cancer, 114, pp.96~102 (2017)
- Kobayashi Y, "Not all epidermal growth factor receptor mutations in lung cancer are created equal : Perspectives for individualized treatment strategy", Cancer Sci, 107, pp.1179~1186 (2016)
- Vyse S, "Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer", Signal Transduct Target Ther, 4, pp.5~ (2019)
- Voon PJ, "EGFR exon 20insertion A763-Y764insFQEA and response to erlotinib : letter", Mol Cancer Ther, 12, pp.2614~2615 (2013)
- Robichaux JP, "Mechanisms and clinical activity of an EGFR and HER2exon 20-selective kinase inhibitor in non-small cell lung cancer", Nat Med, 24, pp.638~646 (2018)
- Rosenbaum JN, "Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer", Mod Pathol, 31, pp.791~808 (2018)
- Ali SM, "Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization", Oncologist, 21, pp.762~770 (2016)
- Pekar-Zlotin M, "Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer", Oncologist, 20, pp.316~322 (2015)
- van der Wekken AJ, "Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer", Clin Cancer Res, 23, pp.4251~4258 (2017)
- Cabillic F, "ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?", ESMO Open, 3, pp.e000419~ (2018)
- Lin C, "Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer", Lung Cancer, 131, pp.62~68 (2019)
- 최창민, "Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014", Cancer Research and Treatment, 51(4), pp.1400~1410 (2019), 대한암학회